Mirvaso (brimonidine)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 CONTRAINDICATIONS MIRVASO topical gel is contraindicated in patients who have experienced a hypersensitivity reaction to...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts